About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Managing High Risk/Relapsed Follicular Lymphoma
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Nathan H. Fowler
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Nathan H. Fowler
235 views
October 25, 2018
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:18
Treatment Considerations in CLL: Challenging Patient Cases
Treatment Considerations for Ibrutinib-Intolerant Patients - A Patie…
Feat.
M. Shadman
Featured Video
24:55
Treatment Considerations in CLL: Challenging Patient Cases
Treatment Considerations in Front-line CLL
Feat.
A. Zelenetz
Related Content
AUTOPLAY
ON
06:33
Christopher Flowers
FDA Approval of Zanubrutinib in R/R FL: What You Need to Know
13:56
SOHO 2023 Eleventh Annual Meeting
Follicular Lymphoma Management: What Is the New Order?
Feat.
B. Kahl
27:51
Louisville Hematology Highlights
Summary of Recent Advances in Follicular Lymphoma
Feat.
S. Gaballa
08:58
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Zanubrutinib + Obinutuzumab vs. Obinutuzu…
Feat.
C. Flowers
26:58
Total Health
Update on Cellular Therapy in Lymphoma
Feat.
B. Randolph
10:36
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in…
Feat.
R. Merryman
31:12
UChicago Medicine
Practice Changing Abstracts in NHL and HL From ASH 2023
Feat.
S. Smith
42:09
University of Colorado Department of Medicine
Immunotherapy in Lymphomas: The Present and the Future
Feat.
M. Kamdar
03:33
PrecisCa
Mosunetuzumab in R/R Follicular Lymphoma
Feat.
M. Kamdar
27:49
MyCancerHaven
Overview of the Diagnosis and Treatment of Follicular Lymphoma
Feat.
R. Vij,
T. Fehniger
21:19
MyCancerHaven
Experts Discuss the Use of Bispecific Antibodies in NHL
Feat.
R. Vij,
B. Kahl
15:08
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Sequencing Therapy in Indolent Lymphoma - Treatment Choic…
Feat.
L. Nastoupil
17:19
SOHO Turkey 2023
SOHO Turkey 2023: How I Treat Follicular Lymphoma
Feat.
J. Lister
04:16
GRACE
Mosunetuzumab for R/R Follicular Lymphoma
Feat.
T. Phillips
03:42
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation,…
Feat.
G. Perini
36:10
University of Colorado Division of Hematology
2023 Denver ASH Review: Updates in CLL and Lymphoma
Feat.
A. Major
15:11
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Lymphoma Bispecific Antibody Therapy and Management of CRS
Feat.
D. Land,
M. Hughes
11:12
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: Indolent B-Cell Lymphoma
Feat.
L. Nastoupil
12:43
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?
Feat.
C. Jacobson
38:55
Indy Hematology Review
Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellul…
Feat.
G. Salles